Bronchogen

Bronchogen is a four-amino-acid synthetic peptide (Ala-Glu-Asp-Leu, abbreviated AEDL) from the Khavinson library of tissue-specific peptide bioregulators ³. It was developed as the lung-targeted member of a panel that includes cardiogen for heart tissue, prostamax for prostate tissue, pancragen for pancreas tissue, and vesugen for endothelium ³.

The compound is studied for bronchial and lung tissue support. The strongest functional evidence comes from rats with nitrogen dioxide induced COPD, where a one-month course reversed airway remodeling and normalized inflammatory markers ¹. In human cell culture, Bronchogen restored differentiation signals in aging bronchial epithelial cells ³.

Evidence level

The evidence base is entirely preclinical. No published human trial has tested the peptide, and most functional lung data come from a single research ecosystem ¹. Mechanism work is stronger and comes from several laboratories ⁵. This places Bronchogen in the same category as other unapproved peptide bioregulators: a real mechanistic story that has not yet reached clinical validation.

Bronchogen works as a nuclear-acting gene regulator rather than a classic receptor agonist. In cell experiments, short peptides from the same family cross the cell membrane and enter the nucleus and nucleolus, giving Bronchogen direct access to DNA ⁶.

DNA binding and chromatin effects

• Sequence preference: Bronchogen binds DNA regions containing CNG and CTG sequences. CNG sites are common targets of cytosine DNA methylation, and binding changes with methylation status ⁶.
• Genome stabilization: It raises DNA melting temperature by 3.1°C at a narrow peptide-to-base-pair ratio, suggesting occupancy-limited binding rather than a simple linear response ⁵.
• Histone interaction: It binds the N-terminal regions of histones H1, H2B, H3, and H4 ⁷. Histones are proteins that package DNA, and modifying that package changes which genes can be read. Bronchogen alters chromatin conformation through this interaction ⁹.
• Methylation machinery: In plant models, the peptide changes expression of DNA and lysine methyltransferase genes, the enzymes that write methylation marks ¹⁰.

From DNA to tissue repair

In aging human bronchial epithelial cell cultures, Bronchogen restored expression of the differentiation signals CXCL12 and Hoxa3. The response was stronger in aged than young cultures and was tissue-specific, which fits a repair-oriented epigenetic program ³. Lung explants from rats responded at 0.05 ng/mL ⁸. In the rat COPD model, that program translated into restored ciliated cells and normalized airway structure and inflammatory markers ¹.

No published human pharmacokinetics exist, so how much peptide reaches bronchial tissue at a given dose is unknown ¹.

Bronchogen's documented effects are preclinical: no human trial has confirmed them in people. The data divide into functional lung outcomes and cellular mechanism findings.

Functional outcomes in the rat COPD model

• Airway remodeling reversal: One month of treatment reversed goblet cell hyperplasia, squamous metaplasia, lymphocytic infiltration, and emphysema, and restored ciliated epithelial cells ¹.
• Immune and surface-tension markers: Treated rats had normalized bronchoalveolar lavage cell composition and cytokine-enzyme profiles, reduced neutrophilic inflammation, and increased secretory IgA and surfactant protein B ².
• Safety signal in the same model: The rat studies reported no adverse findings and described normalization rather than immune overactivation ¹.

Human cell and tissue findings

• Differentiation markers: In late-passage human bronchial epithelial cultures, the peptide increased CXCL12 and Hoxa3, with a stronger effect in aged cells ³.
• Lung explant growth: Organotypic lung explants from young and aged rats were stimulated, not injured, at 0.05 ng/mL ⁸.

Mechanistic effects

• DNA binding and stabilization: Bronchogen discriminates CNG and CTG sequences and raises DNA melting temperature by 3.1°C in a saturable window ⁵.
• Histone targeting: It binds histones H1, H2B, H3, and H4 and changes chromatin conformation ⁷.
• Gene expression: In plants, AEDL modulates developmental gene families and raises glutathione about 3.24-fold ⁴.

These in vitro and animal findings establish mechanism but not human efficacy.

Published dosing is limited. The rat COPD studies used a one-month course of Bronchogen, but the abstracts do not report a mg/kg dose or route ¹. In tissue culture, lung explants responded to 0.05 ng/mL ⁸, and plant gene-regulation effects appeared at 10^-7 to 10^-9 M ⁴.

Human dosing comes from community and practitioner protocols, not published trials. The common injectable schedule is 0.5 to 2 mg subcutaneously once daily for 10 to 20 days, extendable to 30 days for chronic pulmonary pathology. Body-weight scaling is usually about 7 to 28 mcg/kg/day, but many protocols use flat dosing because DNA binding saturates in a narrow concentration window ⁵.

Route considerations

• Subcutaneous: the standard community route.
• Intranasal or inhaled: has a lung-targeting rationale from the tissue-specific mechanism ³, but no published human dose exists.
• Intramuscular: used in some Khavinson peptide protocols, with no demonstrated advantage over subcutaneous.
• Oral forms: not established.

Course patterns

• 10-day assessment course: community protocols often start with 0.5 mg daily to assess response.
• 20 to 30 day repair course: chronic pulmonary protocols escalate to 2 mg daily, repeating every 3 to 6 months.
• Post-infection recovery: 10 days on and 10 days off for 2 to 3 cycles is a practitioner variant.

The one-month rat course is the main duration anchor from published work ¹. No human dose-response study exists.

Bronchogen ships as a lyophilized powder and is freely soluble in aqueous buffers used for DNA-binding and cell-culture assays ⁵. Reconstitute with bacteriostatic water containing 0.9% benzyl alcohol for multi-dose handling, or sterile water for immediate use.

Mixing and handling

• Add the diluent slowly down the vial wall and roll gently. Do not shake, because foaming can damage the peptide.
• Let a cold vial reach room temperature before adding diluent to avoid condensation.
• Keep the solution refrigerated at 2 to 8°C after mixing. Do not freeze the reconstituted solution.

Storage

• Lyophilized powder: long-term storage at -20°C, or 2 to 8°C for short periods. Keep it dry, desiccated, and protected from light.
• Reconstituted solution: refrigerate at 2 to 8°C and use within 14 to 30 days under community storage guidance.
• Discard cloudy solution and avoid repeated freeze-thaw cycles.

The calculator below can adapt the vial size and diluent volume to a target research dose. No formal degradation-kinetics study exists; the one-month rat treatment course provides only indirect evidence of activity over a repeated-administration window ¹.

No formal drug-drug interaction studies exist for Bronchogen. The following reflects mechanistic inference from animal, cell, and plant work plus community practice, not clinical data.

Conventional medications

• Corticosteroids: theoretical additive effect. The rat studies show anti-inflammatory and epithelial repair outcomes that differ from glucocorticoid action ¹, so the overlap may be additive, but it is untested.
• NSAIDs: theoretical additive anti-inflammatory load; no study exists.
• Immunosuppressants: direction is unclear. Bronchogen increased secretory IgA and mucosal immune markers in treated rats ², which could matter in autoimmune or transplant protocols.
• DNA methyltransferase inhibitors, HDAC inhibitors, and other epigenetic drugs: theoretical caution. Bronchogen binds DNA at CNG/CTG sequences, reads cytosine methylation status, and binds histones ⁶, so it could modify the effect of chromatin-directed therapies.
• Autophagy modulators: speculative. In plant cells, AEDL activates autophagy through TOR downregulation and ATG8 upregulation ¹².

Supplements and peptide combinations

• Glutathione or N-acetylcysteine: likely additive antioxidant support. AEDL raised glutathione roughly 3.24-fold in plants ¹³.
• Other Khavinson peptides: Epitalon, Pinealon, and Testagen share DNA and histone binding ⁶, so stacked use may add epigenetic load.
• Vitamins C and E: AEDL reduced oxidative-stress markers in salt-stressed plants ¹⁴, but this has not been tested alongside supplements in humans.
• BPC-157 class repair peptides: no published interaction data; practitioner stacks pair them with Bronchogen for post-infection respiratory recovery.

No adverse peptide-peptide interaction has been documented. The main shared risk across multiple DNA-binding bioregulators is additive gene-regulatory load, which remains unmeasured in humans ⁶.

Published work does not describe receptor desensitization or tachyphylaxis. The cycling pattern is based on a saturating DNA-binding window, short-course rat efficacy, and practitioner consensus.

Community cycle patterns

Pattern	On period	Off period	Notes
Standard short course	10 days	20 to 30 days off	2 to 4 courses per year for maintenance
Extended repair course	20 to 30 days	4 to 8 weeks off	Mirrors the one-month rat regimen 1
Acute recovery course	10 to 14 days	Until symptoms recur	Used during or after respiratory infection

A cumulative-exposure cap of roughly 30 to 45 total days per six months appears in practitioner guidance. The rationale is that DNA stabilization and binding are saturating: adding more peptide beyond a molar ratio of about 0.01 to 0.055 does not increase DNA melting temperature ⁵. Bronchogen's differentiation effects were strongest in aged or depleted bronchial cultures, consistent with restoring lost function rather than producing continuous gains ³. Autophagy activation in plant cells ¹² is another reason community protocols use pulsed rather than open-ended exposure. No long-term continuous human safety data exist.

Bronchogen is most often discussed with other peptide bioregulators from the Khavinson family. No controlled trial has tested these combinations; the reasoning is component-based.

Peptide bioregulator combinations

• Epithalon (Ala-Glu-Asp-Gly): differs from Bronchogen by one amino acid. Both modulate developmental gene families at low concentrations ⁴ and share DNA/histone binding properties ⁶, but they have distinct target-site preferences.
• Vilon and other short bioregulators: commonly cycled in the same Khavinson-style regimens.
• Cardiogen, Prostamax, and Pancragen: tissue-matched companions. In organotypic culture, each acted mainly on its own target tissue at roughly 0.05 ng/mL ⁸, supporting multi-tissue peptide programs with Bronchogen.
• Repair peptides such as BPC-157 class compounds: no published interaction data. Practitioner stacks pair them with Bronchogen for post-infection lung recovery.
• Glutathione or N-acetylcysteine: a sensible antioxidant overlap based on Bronchogen's glutathione-raising effect in plants ¹³, though the interaction is unstudied in humans.

The main caution is additive epigenetic load when several DNA-binding peptides are used together ⁶. No direct adverse combination has been reported.

Bronchogen is not approved by the FDA, the EMA, or another major regulatory authority for human therapeutic use. It is sold as a research peptide internationally and as a parapharmaceutical peptide bioregulator in Russia and CIS markets. The supporting dossier is preclinical: rat COPD studies ¹, human bronchial cell cultures ³, and in vitro mechanism work ⁵.

United States

Bronchogen is not scheduled under the Controlled Substances Act, and tetrapeptides are not scheduled as a class. It is not on the FDA 503A bulks list, so lawful pharmacy compounding from approved bulk substances is not established. Marketing as a dietary supplement would face new dietary ingredient and misbranding scrutiny, and the FDA has not classified Bronchogen as a dietary ingredient.

Europe, UK, and Australia

• EU: no centralized marketing authorization or orphan designation.
• UK: it is an unlicensed medicine; supply outside the MHRA unlicensed-medicines framework is not lawful.
• Australia: it is not on the ARTG, and import of unapproved injectable peptides generally requires an exemption.

Sports

Bronchogen is not named on the WADA Prohibited List. The S2 peptide category covers named compounds only. Its documented actions are restorative and anti-inflammatory in the lung ¹, not performance enhancing, and no athlete sanctions are documented.

Regulatory authorization has not followed the preclinical research.

No published human adverse-event data exist. The highest available safety evidence is from rat COPD studies.

Reported safety in animal work

One-month Bronchogen courses did not produce adverse findings in the rat COPD models. Treatment normalized neutrophilic inflammation, cytokine-enzyme profiles, and structural remodeling, and increased protective markers rather than causing immune overactivation ¹.

Community-reported effects

Community protocols report mostly mild, transient effects: injection-site redness or discomfort, first-dose fatigue, headache, nasal irritation with intranasal use, and a brief increase in sputum production in chronic bronchitis users. These are not systematic trial data.

Theoretical and unstudied risks

• Epigenetic off-target effects: nuclear penetration, histone binding, and chromatin changes are demonstrated ⁶, but chronic airway stem-cell consequences are unknown.
• Methylation-sensitive chemotherapy: interaction with hypomethylating agents or DNA-damaging drugs has not been studied ⁶.
• Autophagy and cell-death signaling: in plant root cells, AEDL suppressed TOR and induced autophagy-related programmed cell death markers ¹². Whether mammalian airway cells behave the same way is unstudied.
• Immunogenicity: the peptide is only four amino acids and no specific antibody data exist, but injectable peptides carry a general hypersensitivity risk.
• Long-term reversibility: whether chromatin effects revert after washout has not been tested.

Populations with the largest gaps

No data exist for pregnancy, breastfeeding, children, or immunocompromised people. A DNA- and histone-binding peptide is a poor candidate during organogenesis ⁶. Active malignancy and concurrent DNA-directed cancer treatment are relative caution areas because the compound interacts with chromatin ⁹. In contrast, the differentiation signal was strongest in aged bronchial cultures, making older tissue the best-aligned population from a mechanism standpoint ³.

Practical monitoring from the rat endpoints

Community monitoring guidance translates the rat readouts into simple tests: baseline and post-course hs-CRP, CBC with differential, spirometry or peak flow, and symptom tracking for cough, sputum, and dyspnea ¹. New fever, hemoptysis, or worsening hypoxemia are red flags for medical evaluation independent of peptide use.